Autonomous microfluidic electrochemical nano-biosensors for highly sensitive and selective detection and monitoring of biomarkers

为快速检测生物流体标记物而开发的当前即时检测测定和装置正在应对自动化、多路复用、定量测量、再现性、可扩展性或成本的挑战中的至少一个。该项目旨在开发一种新的可扩展和可重复的CApillary Microfluidic Electrochemical Nano-biosensing（CAMEN）平台，该平台能够实现复杂的定量生物测定的完全自动化，以实现生物标志物的低成本和即时检测。目标一：开发可重复和超灵敏的电化学纳米生物传感器;目标#2：开发毛细管微流体组件和CAMEN平台;目标#3：使用CAMEN平台检测加标/临床样品中的生物标志物。在两年结束时，我们将展示导电纳米材料/油墨的新型组合物的生产及其在柔性基底上的丝网印刷，使电极能够在一个步骤中转化为电化学纳米生物传感器。该项目还将导致开发一种新的微流体平台，该平台具有已开发的特征毛细管微流体组件库，并且一旦组合，就可以将复杂的电化学生物传感协议自动化到一个芯片中。我们提出的基于CAMEN的生物测定将1）是自动化的和定量的样品-结果测试，2）是模块化的并且容易适应于进行新的测定，3）具有在一个单一试剂盒中同时检测各种类型的生物标志物的多重能力，4）是快速的（<20分钟）和低成本的（<$15-20），和5）由于无线信号传输到网络应用程序和云系统，与数字健康监测兼容，符合加拿大新兴数字健康平台的需求。该项目将通过创造对加拿大产品和与微米和纳米技术、诊断平台和医疗设备相关的知识产权的需求，为加拿大带来经济利益。

The present point-of-care assays and devices developed for rapid detection of biofluid markers are dealing with at least one of the challenges of automation, multiplexing, quantitative measurement, reproducibility, scalability, or cost. This project aims to develop a new scalable and reproducible CApillary Microfluidic Electrochemical Nano-biosensing (CAMEN) platform which enables full automation of complex quantitative bioassays for low-cost and point-of-care detection of biomarkers. Objective #1: Development of reproducible and ultrasensitive electrochemical nano-biosensors; Objective #2: Development of capillary microfluidic components and the CAMEN platform; Objective #3: Employment of the CAMEN platform for detecting biomarkers in spiked/clinical samples. At the end of the two years, we will demonstrate the production of novel compositions of conductive nanomaterials/inks and their screen-printing on flexible substrates, enabling the conversion of electrodes to electrochemical nano-biosensors in one single step. The project will also lead to the development of a new microfluidic platform with a developed library of characterized capillary microfluidic components, and once combined, can automate complex protocols of electrochemical biosensing into one single chip. Our proposed CAMEN-based bioassays would 1) be automated and quantitative sample-to-result tests, 2) be modular and easily adaptable for making new assays, 3) have multiplexing capability for detecting various types of biomarkers simultaneously in one single kit, 4) be rapid (<20 min) and low-cost (<$15-20), and 5) be compatible with digital health monitoring due to the wireless signal transfer to Web-App and Cloud-systems, aligned with the needs of emerging digital health platforms in Canada. This project will lead to economic benefits to Canada by creating demands for Canada's products and IPs related to micro- and nano-technologies, diagnostic platforms, and medical devices.